Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years.

Trial Profile

Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2016

At a glance

  • Drugs Influenza A virus vaccine-H1N1 (Primary) ; AS03A
  • Indications Influenza A virus H1N1 subtype; Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms FLU-D-PAN-H1N1-021
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 29 Dec 2010 Actual end date (1 Aug 2010) added as reported by ClinicalTrials.gov.
    • 29 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Dec 2009 Preliminary results from an interim analysis of the seroconversion and seroprotection rates have been published in the journal Vaccines.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top